Table: Astellas -Q1 group results (IFRS)

Astellas Pharma

01/08/2024 07:00

Aug 1 (Reuters)- 
              Astellas Pharma Inc. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   3 months ended      3 months ended       Year to 
                  Jun 30, 2024        Jun 30, 2023     Mar 31, 2025 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales              473.12              374.99          1.65 trln  
                   (+26.2 pct)         (-1.8 pct)       (+2.9 pct)  
  Operating           50.66               45.79            48.00    
                   (+10.6 pct)         (+38.2 pct)      (+88.1 pct) 
  Pretax              50.50               46.85            43.00    
                   (+7.8 pct)          (+47.9 pct)      (+72.2 pct) 
  Net                 37.60               33.13            30.00    
                   (+13.5 pct)         (+33.5 pct)      (+76.0 pct) 
  EPS Basic         21.00 yen           18.46 yen        16.73 yen  
  EPS Diluted       20.94 yen           18.42 yen                   
  Ann Div                               70.00 yen        74.00 yen  
  -Q2 Div                               35.00 yen        37.00 yen  
  -Q4 Div                               35.00 yen        37.00 yen  
 
  NOTE - Astellas Pharma Inc.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4503.T